NewsBenzingaBTIG réitère son achat sur Innate Pharma, maintient un objectif de prix de 9 $ BTIG réitère son achat sur Innate Pharma, maintient un objectif de prix de 9 $ Benzinga 2026.09.17 15:51 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
